Publications by authors named "V Brescia Morra"
Normative values of the brief international cognitive assessment for multiple sclerosis (BICAMS) in an Italian young adolescent population: the influence of age, sex, and education.
Neurol Sci
November 2024
Background: The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) is the most widely used in clinical practice and the least time-consuming battery to estimate cognitive function in adults with Multiple Sclerosis (MS), while it has been included in few studies on young MS, also because of the absence of normative values.
Objective: The aim of this study is to evaluate the impact of age, sex and education on BICAMS scores in a young adolescent population.
Methods: We administered the BICAMS to 169, 11-to-18-year-old, healthy subjects.
Article Synopsis
- The study explored the link between blood neurofilament light chain (pNfL) levels and various clinical and demographic factors in 685 MS patients, finding that higher pNfL correlates with increased disability and recent disease activity.
- Higher pNfL levels were also associated with cardiovascular comorbidities, while patients on disease-modifying treatments (DMTs) had lower pNfL levels.
- This research reinforces the potential of pNfL as a valuable biomarker for understanding MS progression and the effects of treatment in both clinical and research settings.
Background: While music-based therapy (MBT) has been shown to improve motor and non-motor features in multiple sclerosis (MS), benefits of tango have never been assessed.
Objective: To evaluate the benefits of tango classes on quality of life (QoL), mood, fatigue, gait, balance, perception of cognitive disorder and sexuality in people with MS.
Methods: 7 participants (age 41.
Treatment options for secondary progressive MS (SPMS) are limited, especially considering that the new drugs recently approved are licensed for actively relapsing patients. We aimed to compare the disability progression in a real-world cohort of SPMS patients treated with natalizumab (NTZ) or interferon beta-1b (IFNb-1b). This multicenter retrospective enrolled patients with a diagnosis of SPMS according to 2014 Lublin criteria, who received NTZ or IFNb-1b for at least 48 months between the 1st June 2012 and the 15th May 2018 at 33 Italian MS centers contributing to the Italian MS Registry NTZ or IFNb-1b.
View Article and Find Full Text PDF